SCHEMBL27225358

SCHEMBL27225358

Cc1cc(Br)c[n+](N)c1N.Cc1cc(C)c(S(=O)(=O)[O-])c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAPGEF4 Q8WZA2 6/20 0.36
▸ F2 P00734 3/20 0.34
▸ PRSS1 P07477 3/20 0.34
▸ PRSS2 P07478 3/20 0.34
▸ PRSS3 P35030 3/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP8 P22894 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ MAPK1 P28482 3/20 0.33
▸ CYTH2 Q99418 1/20 0.33
▸ MEN1 O00255 2/20 0.31
▸ NSD2 O96028 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ POLB P06746 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ THRB P10828 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28628697 0.90 RAPGEF4 (0.35) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL31746006 0.84 F2 (0.33) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL20874147 0.81 RAPGEF4 (0.40) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL30002890 0.81 RAPGEF4 (0.38) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL616980 0.81 RAPGEF4 (0.38) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL21561311 0.80 CYP3A4 (0.33) MAPK1ALDH1A1TDP1
SCHEMBL28653697 0.80 MAPT (0.39) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL16913904 0.79 RAPGEF4 (0.36) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL21630876 0.79 RAPGEF4 (0.33) RAPGEF4F2PRSS1PRSS2PRSS3
SCHEMBL31153489 0.79 RAPGEF4 (0.38) RAPGEF4F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608839-A1 SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS Protego Biopharma, Inc. (US) 2025-09-03 — — EP disclosed
US-20240174695-A1 Spirocycle Containing Bicyclic Heteroaryl Compounds PROTEGO BIOPHARMA, INC. 2024-05-30 — — US disclosed
WO-2024092040-A1 SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS PROTEGO BIOPHARMA, INC. (US) 2024-05-02 — — WO disclosed
CN-109641895-B Indole compounds substituted with [1, 2, 4] triazolo [1, 5-a ] pyridyl 百时美施贵宝公司 2021-09-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174695-A1 Spirocycle Containing Bicyclic Heteroaryl Compounds BCL6, BCL6B, BCL9 RAPGEF4 2229/4885F2 3797/4885PRSS1 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback